Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
5'-Deoxy-5'-methylthioadenosine phosphorylase (MTAP) is involved in the salvage of adenine and methylthio moieties of 5'-deoxy-5'-methylthioadenosine, a byproduct of polyamine synthesis, to adenine nucleotides and methionine, respectively. The gene encoding MTAP, MTAP, is frequently codeleted along with the tumor suppressor gene p16 in malignant cells bearing homozygous deletions in the chromosome 9p21 region. p16-, MTAP- malignant cells have been shown to be more susceptible to the purine de novo inhibitory actions of antifolates such as methotrexate than are p16+, MTAP+ cells. To understand the underlying mechanism, we reintroduced MTAP activity into two p16-, MTAP- cell model systems, the MiaPaCa-2 and PANC-1 human pancreatic carcinoma cell lines, by transfection with MTAP cDNA. It was found that transfection with MTAP cDNA (i) restored both the MTAP-dependent adenine and methionine salvage pathways, (ii) decreased the rates of purine de novo synthesis (18-47% lower than the wild-type or sham-transfected counterparts), and (iii) decreased cellular sensitivity to the antipurine-related growth-inhibitory actions of methotrexate and azaserine. These data support the hypothesis that operation of the MTAP-dependent adenine salvage pathway renders MTAP+ cells less dependent on de novo purine synthesis and hence less susceptible than MTAP- malignant cells to the growth-inhibitory actions of agents (e.g. antifolates) whose mechanism of action in part involves the de novo purine pathway. These findings provide a theoretical basis for the relatively selective action certain antifolates may have against MTAP-deficient malignancies.
Chen
Z H
ZH
Cancer Center, University of Massachusetts Medical Center, Worcester, Massachusetts 01655, USA.
Olopade
O I
OI
Savarese
T M
TM
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000962:Antimalarials / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001377:Azaserine / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000235:genetics*; D002452:Cell Count / Q000187:drug effects; D018076:DNA, Complementary / Q000187:drug effects* / Q000378:metabolism; D003839:Deoxyadenosines / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008715:Methionine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000378:metabolism*; D011683:Purine-Nucleoside Phosphorylase / Q000235:genetics* / Q000378:metabolism; D011687:Purines / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000378:metabolism; D013872:Thionucleosides / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D000962:Antimalarials; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D018076:DNA, Complementary; D003839:Deoxyadenosines; D011687:Purines; D012333:RNA, Messenger; D013872:Thionucleosides; C034064:2-fluoroadenosine; C008500:5'-methylthioadenosine; D001377:Azaserine; D008715:Methionine; D011683:Purine-Nucleoside Phosphorylase; C021784:5'-methylthioadenosine phosphorylase; D000241:Adenosine; C030985:purine; D008727:Methotrexate